Research & Development

BioMed X Launches XBridge Program to Support U.S. Reacsearchers Amid NIH Funding Cuts

As research institutions throughout the United States grapple with increasing instability, many are being forced to respond to the growing consequences of widespread funding...

Taiho spends $400 million with a Swiss partner to “turbocharge” three ADCs to the clinic

Taiho Pharmaceutical has paid Otsuka $400 million in upfront purchase of the Araris Biotech ADC linker platform in Switzerland. Araris collaborated with Taiho Pharmaceutical after...

Élancé Therapeutics Joins the Race to Develop Next-Generation Obesity Therapies

China-based Harbour BioMed has recently announced the establishment of a new biotechnology company, Élancé Therapeutics. This initiative is focused on developing bispecific antibodies designed...

Roche Comes Out With Novel ‘Sequencing-By-Expansion’ Approach

Roche has proposed a fresh kind of genetic analysis. This process, which the company refers to as sequencing-by-expansion, is a patented technique that involves...

Sionna Therapeutics Targets $156 Million in IPO to Advance Cystic Fibrosis Research

Sionna Therapeutics, a biotechnology firm headquartered in Waltham, Massachusetts, is preparing to raise up to $156 million through an initial public offering (IPO) as...

Oculis’ Phase 2 Study Explores OCS-05 for Optic Nerve Inflammation

A phase 2 clinical trial has assessed the effectiveness and safety of OCS-05, a peptidomimetic small molecule developed by Oculis, for patients with optic...

Research finds Merck’s treatment of lung disease can lower chance of death

Merck has released that its drug, Winrevair, reduced the risk of death in patients suffering from a rare condition that causes high blood pressure...

GSK Responds to Pfizer’s RSV Approval with Data Aiming for Similar Approval in Younger Adults

Two early-phase study trials suggest that GSK’s RSV vaccine, Arexvy, may benefit certain high-risk subgroups of younger adults and could potentially serve a broader...

Latest news

Merck Signs $493M Agreement to Use Cyprumed’s Oral Peptide Platform

Merck & Co. is taking a significant step toward transforming its peptide therapies into convenient oral tablets through a...

The late-stage research of Bristol Myers’ heart disease medication falls short of its primary objectives

Bristol Myers Squibb disclosed that its drug stavartanate did not successfully improve functional capacity or symptom intensities in heart...

J&J MedTech presents the first Ottava surgical robot clinical cases

Johnson & Johnson MedTech successfully conducted the initial clinical use of Ottava surgical robot through a minimally invasive gastric...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you

Amgen Cuts Lupus Programs Along with Lilly

Amgen has discontinued both of its mid-stage...

Life Sciences Voice Top Five Newsletter

Welcome to this week’s edition of the Life Sciences...